MetaCap

Axonex AI Group Limited Class A (AXNX)

NASDAQ: AXNXConsumer DiscretionaryBusiness ServicesUSD

0.8301-0.0749 (-8.28%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AXNX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$10.37
52-week range
0.68 – 18.35
Day range
0.83 – 0.9435
Volume / Avg
26.95K / 2.01M
Beta
—

52-week range

$0.68$18.35

AXNX stock today

Axonex AI Group (AXNX) closed at $0.8301 on Nov 20, down 8.28% (-$0.0749), versus the S&P 500's 3.70% decline. Trading was light, with 26.95K shares changing hands, about 1% of the average daily volume. Shares are 95.5% below their 52-week high of $18.35 and 22.1% above the 52-week low of $0.68, near the bottom of the past year's range.

Axonex AI Group has posted a net loss over the last twelve months (EPS of -$10.37), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Axonex AI Group

Company profile

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence.

Industry
Business Services
CEO
Mr. Raymond W. Cohen
Headquarters
Irvine, CA
Employees
797
IPO year
2025

Financial highlights

Full financials

Axonex AI Group reported a net loss of $10.3 million, compared with a loss of $1.5 million a year earlier. Diluted earnings per share came in at -$4.15.

Axonex AI Group annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023
Revenue—$3.05M$4.08M$2.44M
Growth—-25.28%+67.36%—
Net income$-10.31M$-1.46M$783.44K$819.42K
EPS (diluted)$-4.15$-0.68$0.37$0.04

Analyst forecast

Forecast

Consensus (5 analysts)

hold

  • Strong buy 0
  • Buy 1
  • Hold 4
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

AXNX news

All AXNX news

Axonex AI Group peers

Consumer Discretionary sector
AXNX peer companies
CompanyPrice% ChgMarket capCompare
KRKR36Kr Holdings Inc. ADR2.56-3.40%$5.05Mvs AXNX
BAOSBaosheng Media Group Holdings Limited0.1166-8.91%$3.89Mvs AXNX
OLBThe OLB Group Inc.0.115-4.33%$3.59Mvs AXNX
TGLTreasure Global Inc.3.88-5.13%$3.56Mvs AXNX
CJMBCallan JMB Inc.0.301-7.10%$3.21Mvs AXNX
QHQuhuo Limited Class A3.06-1.29%$8.42Mvs AXNX
UKUcommune International Ltd Class A1.10-9.84%$745.75Kvs AXNX
XHLDTEN Holdings Inc.0.6402-3.03%$9.90Mvs AXNX

Indexes, lists and sector

Axonex AI Group stock FAQ

What is Axonex AI Group's stock price today?

AXNX last traded at $0.8301 as of Nov 20, 4:00 PM EST, down 8.28% on the day. Prices are delayed at least 15 minutes.

Does Axonex AI Group pay a dividend?

No. Axonex AI Group does not currently pay a regular cash dividend.

Who is Axonex AI Group's CEO?

Mr. Raymond W. Cohen is the chief executive officer of Axonex AI Group Limited Class A, which has about 797 employees.

Has AXNX ever split its stock?

Yes. The most recent AXNX stock split was a 1-for-3 split on Oct 22, 2026.

What is the AXNX 52-week high?

The 52-week high for AXNX is $18.35 and the 52-week low is $0.68. The stock is currently 95.5% below its high.

Compare AXNX